- Stocks
- Pharma & Healthcare
- Glenmark Pharmaceuticals
Glenmark Pharmaceuticals share price
NSE: GLENMARKPharma & HealthcareDrug Manufacturers - Specialty & Generic
Glenmark Pharmaceuticals at a glance
Glenmark Pharmaceuticals (NSE: GLENMARK) closed at ₹2,196.40 on 22 Oct 2026, down 0.16% on the day. With a market capitalisation of ₹61,909 Cr, it ranks 159th by market cap among the 4,183 NSE companies Pivot tracks (a mid-cap company by SEBI's rank bands). It belongs to the Pharma & Healthcare sector; its industry is Drug Manufacturers - Specialty & Generic.
At its last close the stock traded at 45.5× trailing earnings, against a return on equity of 13.0% in FY26. Over the past year the share price has risen 16.4%. Its 52-week range is ₹1,792.60 (28 Oct 2025) to ₹2,537.60 (28 Aug 2026); the last close is 13.4% below the high. In Q1 FY27, the quarter ended 30 Jun 2026, revenue was ₹3,932 Cr (+28.5% year on year) and net profit ₹483 Cr (+928.0%), on a consolidated basis. Promoters held 46.65% of the company as of 30 Jun 2026.
Key numbers
- Market cap
- ₹61,909 CrRank 159 on NSE
- P/E (trailing)
- 45.5×
- Price to book
- 5.73×FY26
- EPS (TTM)
- ₹63.71to Q1 FY27
- ROE
- 13.0%FY26
- ROCE
- 33.0%FY26
- Debt to equity
- 0FY26
- Net profit margin
- 8.0%FY26
- Book value / share
- ₹372.51FY26
- 52-week high
- ₹2,537.6028 Aug 2026
- 52-week low
- ₹1,792.6028 Oct 2025
- 1-year return
- +16.4%
- RSI (14-day)
- 34.3
Returns to 22 Oct 2026
| Period | 1 day | 1 week | 1 month | 3 months | 1 year |
|---|---|---|---|---|---|
| Price change | −0.16% | −2.1% | −10.5% | −0.6% | +16.4% |
Glenmark Pharmaceuticals quarterly results
| Quarter | Q2 FY25 | Q3 FY25 | Q4 FY25 | Q1 FY26 | Q2 FY26 | Q3 FY26 | Q4 FY26 | Q1 FY27 |
|---|---|---|---|---|---|---|---|---|
| Revenue | ₹3,401 Cr | ₹3,302 Cr | ₹3,220 Cr | ₹3,059 Cr | ₹6,004 Cr | ₹3,888 Cr | ₹3,760 Cr | ₹3,932 Cr |
| Revenue YoY | +6.0% | +31.7% | +5.1% | −5.1% | +76.6% | +17.8% | +16.8% | +28.5% |
| Net profit | ₹354 Cr | ₹348 Cr | ₹4 Cr | ₹47 Cr | ₹610 Cr | ₹403 Cr | ₹301 Cr | ₹483 Cr |
| Net profit YoY | — | — | — | −86.2% | +72.2% | +15.9% | +6,779.5% | +928.0% |
| Net margin | 10.4% | 10.5% | 0.1% | 1.5% | 10.2% | 10.4% | 8.0% | 12.3% |
| EPS | ₹12.55 | ₹12.33 | ₹0.16 | ₹1.66 | ₹21.63 | ₹14.29 | ₹10.68 | ₹17.11 |
Glenmark Pharmaceuticals financials
| Item | FY21 | FY22 | FY23 | FY24 | FY25 | FY26 |
|---|---|---|---|---|---|---|
| Revenue | ₹10,944 Cr | ₹12,305 Cr | ₹12,990 Cr | ₹11,813 Cr | ₹13,322 Cr | — |
| Operating profit | ₹1,338 Cr | ₹1,702 Cr | ₹1,634 Cr | ₹937 Cr | ₹1,772 Cr | — |
| Net profit | ₹970 Cr | ₹994 Cr | ₹377 Cr | −₹1,434 Cr | ₹1,047 Cr | — |
| EPS (₹) | ₹34.00 | ₹33.00 | ₹11.00 | −₹53.00 | ₹37.00 | — |
| Cash from operations | ₹1,131 Cr | ₹1,109 Cr | ₹625 Cr | −₹265 Cr | −₹828 Cr | — |
| Total debt | ₹3,889 Cr | ₹2,572 Cr | ₹3,852 Cr | ₹0 Cr | ₹513 Cr | ₹0 Cr |
| Shareholders' equity | ₹7,065 Cr | ₹9,087 Cr | ₹9,474 Cr | ₹7,848 Cr | ₹8,849 Cr | ₹10,512 Cr |
Glenmark Pharmaceuticals shareholding pattern
| Holder | 31 Mar 2025 | 30 Jun 2025 | 30 Sep 2025 | 31 Dec 2025 | 31 Mar 2026 | 30 Jun 2026 |
|---|---|---|---|---|---|---|
| Promoters | 46.65% | 46.65% | 46.65% | 46.65% | 46.65% | 46.65% |
| Foreign institutions | 23.16% | 20.62% | 20.73% | 19.20% | 20.34% | 20.89% |
| Domestic institutions | 14.60% | 17.64% | 18.61% | 20.09% | 19.29% | 18.60% |
| Non-institutions | 15.56% | 15.06% | 13.97% | 14.02% | 13.68% | 13.81% |
Glenmark Pharmaceuticals vs peers
The listed Pharma & Healthcare companies nearest to Glenmark Pharmaceuticals by market capitalisation.
| Company | Price | 1 day | 1 year | Market cap | P/E | ROE |
|---|---|---|---|---|---|---|
| MAXHEALTHMax Healthcare Institute | ₹804.80 | −1.54% | −30.6% | ₹79,237 Cr | 54.6 | 13.4% |
| GLENMARKGlenmark Pharmaceuticals | ₹2,196.40 | −0.16% | +16.4% | ₹61,909 Cr | 45.5 | 12.9% |
| ALKEMAlkem Laboratories | ₹4,972.00 | −0.58% | −9.6% | ₹59,304 Cr | 25.8 | 16.6% |
| ASTERDMAster DM Health | ₹647.20 | −0.46% | −5.5% | ₹57,086 Cr | 101.1 | 8.5% |
| FORTISFortis Healthcare | ₹720.15 | −0.67% | −33.5% | ₹54,659 Cr | 52.3 | 10.5% |
| ABBOTINDIAAbbott India | ₹25,445.00 | −1.57% | −15.3% | ₹53,931 Cr | 34.8 | 33.4% |
| BIOCONBiocon | ₹332.85 | −0.19% | −5.1% | ₹53,829 Cr | 117.6 | 1.1% |
Ask anything about Glenmark Pharmaceuticals
Pivot answers on the live chart with evidence you can check, and tests strategies against GLENMARK's own history. Try: “Why has GLENMARK moved over the last three months?” · “Backtest a 50-day moving-average crossover on GLENMARK over five years” · “Compare GLENMARK with MAXHEALTH on margins and valuation”
Frequently asked questions about Glenmark Pharmaceuticals
What is the share price of Glenmark Pharmaceuticals today?
Glenmark Pharmaceuticals (NSE: GLENMARK) last closed at ₹2,196.40 on 22 Oct 2026. Its 52-week high is ₹2,537.60 and its 52-week low is ₹1,792.60.
What is the market cap of Glenmark Pharmaceuticals?
Glenmark Pharmaceuticals' market capitalisation is ₹61,909 Cr (₹61,909 Cr) at the 22 Oct 2026 close, ranking 159th among the NSE companies Pivot tracks.
What is the P/E ratio of Glenmark Pharmaceuticals?
Glenmark Pharmaceuticals trades at a trailing P/E of 45.5. The median P/E of the 6 closest Pharma & Healthcare peers by market cap is 54.6.
What is the ROE and ROCE of Glenmark Pharmaceuticals?
Return on equity was 13.0% in FY26 and return on capital employed was 33.0% in FY26 (consolidated figures).
Is Glenmark Pharmaceuticals a debt-free company?
Glenmark Pharmaceuticals is close to debt-free: its debt-to-equity ratio was 0 in FY26.
What were Glenmark Pharmaceuticals' latest quarterly results?
For Q1 FY27 (quarter ended 30 Jun 2026), Glenmark Pharmaceuticals reported revenue of ₹3,932 Cr, +28.5% year on year, and net profit of ₹483 Cr, +928.0% year on year.
How has Glenmark Pharmaceuticals stock performed over the last year?
Glenmark Pharmaceuticals' share price has risen 16.4% over the past year, −0.6% over three months and −10.5% over one month, to the 22 Oct 2026 close.
What is the shareholding pattern of Glenmark Pharmaceuticals?
As of 30 Jun 2026: promoters 46.65%, foreign institutions 20.89%, domestic institutions 18.60%, non-institutions 13.81%.
Who are Glenmark Pharmaceuticals' competitors?
The listed Pharma & Healthcare companies closest to Glenmark Pharmaceuticals by market cap are Max Healthcare Institute, Alkem Laboratories, Aster DM Health, Fortis Healthcare, Abbott India and Biocon.
Is Glenmark Pharmaceuticals a good stock to buy?
Pivot does not give buy or sell recommendations. This page sets out Glenmark Pharmaceuticals' price history, valuation, profitability, quarterly results and ownership so you can judge it yourself, and Pivot's chart lets you test a strategy on GLENMARK against its own history before risking money. This is analysis, not financial advice.
Sources and method
Prices: NSE daily closes to 22 Oct 2026 (returns and ratios at the 22 Oct 2026 close). Fundamentals: company filings via Moneycontrol, consolidated where available. Shareholding: exchange shareholding-pattern filings. The 52-week range uses intraday highs and lows; the chart marks closing prices. P/E is the last close over trailing twelve-month EPS. Market-cap rank is among the 4,183 NSE companies Pivot tracks; SEBI's bands call the top 100 large-cap and the next 150 mid-cap. Figures marked “—” are not available rather than zero. This is analysis, not financial advice.
More: all Pharma & Healthcare stocks · companies starting with G · all NSE stocks · this page as text